Q1 Productions Webcast will Address Pressing Regulatory Challenges in the Burgeoning Drug Delivery Industry.

4P Therapeutics - Preclinical Feasibilty - Leaders in Transdermal Research & Development

Q1 Productions Webcast will Address Pressing Regulatory Challenges in the Burgeoning Drug Delivery Industry.

PRLog (Press Release) Feb. 14, 2013 – Q1 Productions, a leading educational provider for the pharmaceutical industry, will be conducting a webinar entitled “Addressing Challenges in Developing Drug Delivery Systems: Navigating Regulatory Requirements in the US” on Tuesday, February 25 at 1 pm EST. This live online meeting will be presented by Alan Smith PhD., Vice President Clinical, Regulatory, and Operations at 4P Therapeutics, a private company focused on the research and development of novel drug delivery technologies and novel drug delivery-based therapeutics.

Innovative drug delivery systems are one of the fastest-growing sectors within the pharmaceutical industry with revenue forecasted to reach $100 billion by 2016 in the US alone. This online seminar will provide attendees with a comprehensive overview of drug delivery systems and US and global drug delivery markets, current applicable FDA guidance, and requirements for demonstrating safety and efficacy for products that contain already approved drugs.

“The introduction of a transdermal glycoprotein inhibitor would have a significant impact on the management of several cardiovascular conditions,” stated Dr. David Lee, Director of the Cardiac Catheterization and Coronary Intervention Laboratories, Stanford University Medical Center. “This innovation would not only enhance the ease-of-use and healthcare costs associated with the traditional uses of this class of drugs, but may also facilitate earlier, pre-hospital administration as well as a number of other new applications.”

With over a decade of experience partnering with multi-national pharmaceutical corporations such as Eli Lilly, Hospira, and Novartis, Dr. Smith brings a wealth of knowledge regarding developing drug, biologic and vaccine delivery systems for treatment and management of diabetes, chronic pain, cardiovascular disease, and infectious diseases. He currently serves on the Editorial Advisory Board of Expert Opinion on Drug Delivery.

Attendees who will find this program to be beneficial include professionals working in: regulatory affairs, delivery device development, drug delivery research and development, business development, strategic product development, pharmaceutical development, drug formulation, and novel drug delivery technologies.

For registration information please visit: www.q1productions.com/WB7007.php (http://www.q1productions.com/WB7007.php#.URPMgGeDRjc)

No Comments

Post A Comment